Oyster Point Pharma To Attend H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference on August 17, 2022
August 15, 2022 08:00 ET
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), (“Oyster Point Pharma”, or “the Company”), a commercial-stage biopharmaceutical company focused on the...
Oyster Point Pharma Reports Second Quarter 2022 Financial Results and Recent Business Highlights
August 11, 2022 16:01 ET
|
Oyster Point Pharma, Inc.
TYRVAYA® (Varenicline Solution) Nasal Spray Achieved Net Product Revenue of $4.7 Million in Q2’22Approximately 30,000 TYRVAYA Prescriptions Filled During the Quarter, with Prescriptions Written by...
Oyster Point Pharma To Report Second Quarter 2022 Financial Results On August 11, 2022
August 08, 2022 16:03 ET
|
Oyster Point Pharma, Inc.
Conference Call and Webcast Scheduled for August 11, 2022, 4:30 p.m. ET PRINCETON, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST) a commercial-stage...
Oyster Point Pharma Announces Expanded Patient Access to TYRVAYA®
July 27, 2022 07:00 ET
|
Oyster Point Pharma, Inc.
TYRVAYA Now Covered by Commercial Prescription Drug Plans Managed by the Nation’s Top Three Pharmacy Benefit Manager (PBM) Group Purchasing Organizations (GPOs)Expanding Patient Access Programs to...
Oyster Point Pharma Announces Operating Expense Streamlining Plan
June 28, 2022 16:05 ET
|
Oyster Point Pharma, Inc.
Plan to Continue to Drive TYRVAYA® Launch with Approximately 150-200 Field-Based Sales Resources Plan Expected to Deliver Expense Savings of Approximately $6-8 Million in the Second Half of 2022...
Oyster Point Pharma Research Selected for Top 5 Poster Session at American Optometric Association's Optometry's Meeting®
June 15, 2022 07:55 ET
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., June 15, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization...
Oyster Point Pharma Reports First Quarter 2022 Financial Results and Recent Business Highlights
May 05, 2022 16:01 ET
|
Oyster Point Pharma, Inc.
TYRVAYA® Nasal Spray Net Product Revenue of $2.7 Million in Q1’22Approximately 19,000 TYRVAYA Prescriptions Filled During the Quarter, with Prescriptions Written by Over 4,500 Unique Eye Care...
Oyster Point Pharma To Report First Quarter 2022 Financial Results On May 5, 2022
May 03, 2022 16:01 ET
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., May 03, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST) a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Oyster Point Pharma to Present New Analyses at the Association for Research in Vision and Ophthalmology (ARVO) 2022
April 27, 2022 08:00 ET
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., April 27, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development, and...
Oyster Point Pharma to Present New Clinical Data at the American Society of Cataract and Refractive Surgery (ASCRS) 2022
April 19, 2022 08:00 ET
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., April 19, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development, and...